|Toxiciy Grade:||4||City/State/Province:||Bimingham, Alabama|
|Treatments:||Biologic therapy||Hospital:||Burmingham Comprehensive Cancer Center|
Patients: This Phase I study involved 17 patients with stage IV melanoma with metastatic lesions. The age range was 36-85 years.
Treatment: Patients were given the investigational agent KW-2871, a monoclonal antibody.
Toxicity: One patient had grade 4 seizures, grade 3 urticaria, and grade 2 fever/chills/rigor. This patient had a history of brain metasteses. Other grade 3 toxicities included laryngeal edema, chest tightness, and urticaria. All patients experienced at least one toxic event.
Results: Survival was not reported because the effectiveness of this treatment was not an aim of the trial, it was to determine doses and toxicities.
Support: This work was supported by Kyowa Pharmaceuticals, which employees one of the authors and developed KW-2871.
Correspondence: Dr. Andres Forero